SCHEMBL6800407

SCHEMBL6800407

Cc1ncc(NC(=O)c2ccccc2)c(=O)n1CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.49
NPC1 O15118 8/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
MAPT P10636 3/20 0.49
TP53 P04637 2/20 0.49
CNR2 P34972 1/20 0.48
POLB P06746 2/20 0.46
CASP1 P29466 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
KCNMA1 Q12791 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
PKM P14618 2/20 0.43
HDAC1 Q13547 1/20 0.43
HCAR3 P49019 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240894 0.86 ELANE (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6245063 0.85 ALDH1A1 (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6805801 0.84 RAB9A (0.53) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6243657 0.82 ALDH1A1 (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6800426 0.82 ALDH1A1 (0.43) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6803058 0.81 NPC1 (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6803430 0.81 ALDH1A1 (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6805612 0.81 HDAC2 (0.46) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6802993 0.81 RAB9A (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL6805406 0.81 HSP90AA1 (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS RAB9A 2244/4885NPC1 1638/4885SMN1; SMN2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.